LENZ THERAPEUTICS INC

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

09 May 2025 09:03:48 By Nasdaq GlobeNewswire

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

07 May 2025 16:05:01 By Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

06 May 2025 16:30:48 By Nasdaq GlobeNewswire

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

30 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

19 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Host Commercial Day on April 15, 2025

03 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming Investor Conferences

24 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming Investor Conferences

12 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

30 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

27 Oct 2024 21:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

21 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Participate in Upcoming Investor Conferences

27 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

14 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

12 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

07 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

15 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

10 Jun 2024 08:00:00 By Nasdaq GlobeNewswire